Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC)

ClinicalTrials.gov ID: NCT07252232

Public ClinicalTrials.gov record NCT07252232. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced May 6, 2026, 8:32 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

RASolute 304: A Phase 3 Multicenter, Open-label, Randomized, 2-Arm Study of Adjuvant Daraxonrasib Versus Standard of Care Observation Following Completion of Neoadjuvant and/or Adjuvant Chemotherapy in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC)

Study identification

NCT ID: NCT07252232
Recruitment status: Recruiting
Study type: Interventional
Phase: Phase 3
Lead sponsor: Revolution Medicines, Inc.; Industry
Enrollment: 500 participants

Conditions and interventions

Conditions

Interventions

daraxonrasib Drug

Drug

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Dec 14, 2025
Primary completion: May 9, 2029
Completion: Jul 9, 2030
Last update posted: Apr 30, 2026

2025 – 2030

United States locations

U.S. sites: 13
U.S. states: 11
U.S. cities: 12

Facility	City	State	ZIP	Site status
University of California, Los Angeles	Los Angeles	California	90404	Recruiting
University of California, San Francisco	San Francisco	California	94143	Not yet recruiting
Hartford Healthcare	Hartford	Connecticut	06103	Recruiting
Community Health Network	Indianapolis	Indiana	46250	Recruiting
University of Kansas Medical Center Research Institute, Inc.	Lawrence	Kansas	66045	Recruiting
Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins	Baltimore	Maryland	21287	Recruiting
Saint Luke's Cancer Institute	Kansas City	Missouri	64111	Recruiting
Columbia University Medical Center	New York	New York	10032	Recruiting
Memorial Sloan Kettering Cancer Center	New York	New York	10065	Recruiting
Taylor Cancer Research Center	Maumee	Ohio	43537	Recruiting
Avera Cancer Institute	Sioux Falls	South Dakota	57105	Recruiting
University of Utah, Huntsman Cancer Institute	Salt Lake City	Utah	94112	Recruiting
Virginia Cancer Specialists	Fairfax	Virginia	22031	Recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 4 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT07252232, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Apr 30, 2026 · Synced May 6, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT07252232 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →